Complement and microglia mediate early synapse loss in Alzheimer mouse models
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 21 of the 28 sources its claims cite were checked for support.
Abstract
Too much cleaning up: The complement system and microglia seek out and destroy unwanted cellular debris for the peripheral immune system as well as excess synapses in the developing brain. Hong et al. now show how the system may go haywire in adults early in the progression toward Alzheimer's disease (AD). Aberrant synapse loss is an early feature of Alzheimer's and correlates with cognitive decline. In mice susceptible to AD, complement was associated with synapses, and microglial function was required for synapse loss. The authors speculate that aberrant activation of this “trash disposal” system underlies AD pathology. Science , this issue p. 712
Overview
CoChat Summary
TL;DR
In Alzheimer mouse models, classical complement proteins C1q and C3 increase and localize to synapses before plaques, and blocking C1q, C3, or microglial CR3 reduces early synapse loss. Soluble Aβ oligomers drive microglial engulfment of synaptic material through a CR3-dependent pathway, suggesting reactivation of developmental synaptic pruning in early AD.
Key findings
- J20 hAPP mice showed significant hippocampal synapse loss at 3–4 months, before plaque deposition; loss occurred in CA1, CA3, and dentate gyrus at 3 months but not in striatum, and was not seen at 1 month.
- C1q was elevated in J20 brains as early as 1 month, region-specifically in hippocampus and frontal cortex, and colocalized with PSD95-positive puncta; Compound E reduced soluble Aβ and C1q deposition, while oligomeric Aβ—but not monomeric Aβ or vehicle—induced C1q deposition and synaptic colocalization.
- Oligomeric Aβ induced synapse loss within 72 h in WT mice but not in C1qa knockout mice; anti-C1q antibody ANX-M1 prevented oAβ-induced synapse loss and LTP impairment, and APP/PS1xC3 KO mice did not show the synapse loss seen in 4-month APP/PS1 hippocampus.
- Microglial CD68 increased in J20 hippocampus and after oAβ; oAβ increased internalized Homer-GFP in microglia, failed to do so in CR3 KO mice, and induced hippocampal synapse loss in WT but not CR3 KO mice.
Methods
- Mouse models included J20 hAPP, APP/PS1, C1qa KO, C3 KO, CR3 KO, and Homer-GFP mice, with WT littermates and ages including 1 month, 3–4 months, and P21.
- Synapse quantification used super-resolution structured illumination microscopy, confocal imaging, and electron microscopy with colocalized pre- and postsynaptic puncta markers including synaptophysin/PSD95, synaptotagmin/homer, and synapsin/PSD95; C1q and C3 colocalization with PSD95 was also measured.
- Interventions included Compound E, intracerebroventricular or tail vein injections of soluble Aβ oligomers, monomers, or vehicle, anti-C1q antibody ANX-M1 or IgG control, acute hippocampal slice LTP recordings, and an in vivo synaptic engulfment assay.
Limitations
- The paper states that specific synaptic C1q receptors are not yet known and that oAβ and C1q may act indirectly through cytokines such as TGFβ, microglial or astrocytic activation, or other pathways including MHCI/PirB.
- The paper states that the complement pathway may not be involved in all pathological routes to AD, including plaque-associated synapse loss, and that future studies are needed to examine plaque-associated synapse loss and other synaptopathies such as tauopathies and Huntington’s disease.
- Evident from the text: the findings are from mouse models and acute hippocampal slices, not human AD tissue or clinical trials, and the study focuses on early pre-plaque mechanisms rather than established plaque-associated neuropathology.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 0 Not valid · 2 Not checked · 48 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [5] Stevens B The classical complement cascade mediates CNS synapse elimination. Cell 2007 131 1164 1178 18083105 source
The Results report C1q localized to synapses in the developing dLGN during synaptic pruning and relocalized to adult retinal synapses in early glaucoma, before significant synapse loss. The Discussion likewise places synaptic C1q relocalization before or concurrent with synapse loss in the glaucoma model. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [27] Stephan AH Barres BA Stevens B The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci 2012 35 369 389 22715882 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that the engulfed synapses are internalized into lysosomal compartments in a manner similar to developmental synaptic pruning (6).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [6] Schafer DP Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. Neuron 2012 74 691 705 22632727 PMC3528177 source
The Results section, “Microglia engulf RGC inputs during a period of active synaptic pruning” (page unavailable), reports that most engulfed RGC inputs colocalized with microglial lysosomal compartments. The Results section, “Microglia engulf presynaptic elements specific to RGCs” (page unavailable), also identifies an RGC presynaptic marker within microglial lysosomes, supporting the proposed similarity to developmental synaptic pruning. (LLM, conf=0.94)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Quantification of colocalized pre- and postsynaptic puncta (synaptophysin and PSD95 (Fig. 1A); synaptotagmin and homer (figs. S1A-D)) revealed a significant loss of synapses in J20 hippocampus at 3-4 months old (mo), an age that precedes plaque deposition (11, 12).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [11] Mucke L High-Level Neuronal Expression of Abeta 1-42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. Journal of Neuroscience 2000 20 4050 10818140 PMC6772621 source
The citation is attached to the statement that 3–4 months precedes plaque deposition, not to the citing authors’ synapse measurements. In “Effects of hAPP mutations on formation of amyloid plaques” (Fig. 4; page not provided), the paper assesses mice at 2–4 months and reports amyloid deposition in APP Sw,Ind mice at 5–7 months; the paper identifies J20 as an APP Sw,Ind line. (LLM, conf=0.91)
- Supportedcites [12] Hong S Dynamic Analysis of Amyloid -Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal A during Age-Related Plaque Formation. Journal of Neuroscience 2011 31 15861 15869 22049429 PMC3227224 source
The citation follows the statement that 3–4 months precedes plaque deposition, rather than the citing authors’ own synapse measurements. The Results section (page unavailable) identifies approximately 3-month-old J20 mice as pre-plaque and describes 3–7-month-old mice as plaque-free. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genome-wide association studies (GWAS) implicate microglia and complement-related pathways in AD (1).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [1] Hong S Dissing-Olesen L Stevens B New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol 2016 doi:10.1016/j.conb.2015.12.004 PMC5479435 26745839 source
The Introduction says GWAS and integrated network studies identify immune-related AD risk pathways implicating microglia. The section on microglia–synapse dysfunction identifies GWAS variants CLU and CR1, both related to complement. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“C1q was also similarly increased in hippocampus of another model of AD, the APP/PS1 mice (15) (Fig. S2C).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [15] Jankowsky JL Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet 2004 13 159 170 14645205 source
The citation identifies the APP/PS1 mouse model, while the citing document points to its own Fig. S2C for the C1q increase. Figure 2 (p. 4) describes APPswe/PS1 double-transgenic mice and shows hippocampal amyloid pathology in that model. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
48 more claims · 5 with their cited sources checked
Create a free account to see all 66 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“increasing evidence demonstrate that immune signaling may not just be a consequence of protein aggregation in the brain, but that it actually causes the buildup of aggregates at the earliest stages of the disease process.15–17”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In neurodegeneration, the complement pathway is activated, and inhibiting the complement proteins C1q or C3 results in less neuroinflammation, Aβ plaques and synapse loss29,30.”
From Exercise plasma boosts memory and dampens brain inflammation via clusterin (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Before the onset of Aβ deposition, microglia engulf synapses opsonized with the complement factors C1q and C3 upon CR3-mediated recognition of C3 (121).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of C1q, C3, or CR3 curbed microglia activation and synaptic loss during amyloid plaque deposition.”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [139]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inappropriate control of the classical complement cascade causes unresolvable inflammation and disease (Hong et al. , 2016; Hansen, Hanson and Sheng, 2018; Morgan, 2018).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Hong et al., 2016
Experimental — accuracy not yet measured
70 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Cited work 10.1038/nn.3560 · retracted 2022-01-13 · notice 10.1038/s41593-021-00877-7 · this paper published 2016-05-06
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519 · cited 2×
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Self-citationRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Synaptic deficits occur in early AD and mild cognitively impaired patients before onset of plaques and are some of the first signs of the neuronal degenerative process (4, 23-25).”
Self-citationTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313 · cited 4×
“Although specific receptors for C1q at synapses are not yet known, C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
InfluentialSelf-citationIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“S11), indicating they are resident cells (22).”
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 3×
“S4), long before Aβ plaques deposit (11, 12), raising the question of whether C1q increase in these pre-plaque brains is dependent on soluble Aβ levels.”
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Cited by
Items 801–900 of 3,347
The subfornical organ is a nucleus for gut-derived T cells that regulate behaviour
Yoshida, T. M., Nguyen, M. T., Zhang, L., Lu, B. Y., Zhu, B., Murray, K. N., Mineur, Y. S., Zhang, C., Xu, D., Lin, E., et al. (2025) · Nature · doi:10.1038/s41586-025-09050-7 · Cited by 76
Yang, R., Liu, S., Zhou, J., Bu, S., & Zhang, J. (2017) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2017.1344989 · Cited by 65
“ANDRO reduced the mRNA levels of TNF-a, IL-1b, COX-2, and iNOS in ab (1-42)-stimulated microglial cells”
BackgroundNadjar, A., Wigren, H., & Tremblay, M. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00250 · Cited by 63
modCHIMERA: a novel murine closed-head model of moderate traumatic brain injury
Sauerbeck, A. D., Fanizzi, C., Kim, J. H., Gangolli, M., Bayly, P. V., Wellington, C. L., Brody, D. L., & Kummer, T. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-25737-6 · Cited by 57
Don't forget astrocytes when targeting Alzheimer's disease
Sadick, J. S., & Liddelow, S. A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14568 · Cited by 57
Understanding microglial diversity and implications for neuronal function in health and disease
De Schepper, S., Crowley, G., & Hong, S. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22777 · Cited by 57
“Now, a similar reactivation of the complement pathway in microglia and relevance to synapse loss has been reported in various models of neurologic diseases (Dejanovic et al., 2018; Hong et al., 2016; Lui et al., 2016; Paolicelli et al., 2017; Sellgren et al., 2019; Shi et al., 2017; Vasek et al., 2016; Vukojicic et al…”
ResultSelf-citationTripathi, A., Whitehead, C., Surrao, K., Pillai, A., Madeshiya, A. K., Li, Y., Khodadadi, H., Ahmed, A. O., Turecki, G., Baban, B., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01065-6 · Cited by 65
Microglial Priming in Infections and Its Risk to Neurodegenerative Diseases
Lima, M. N., Barbosa‐Silva, M. C., & Maron‐Gutierrez, T. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.878987 · Cited by 70
Time-dependent and selective microglia-mediated removal of spinal synapses in neuropathic pain
Yousefpour, N., Locke, S., Deamond, H., Wang, C., Marques, L., Louis, M. S., Ouellette, J., Khoutorsky, A., Koninck, Y. D., & Ribeiro‐da‐Silva, A. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112010 · Cited by 70
Ji, Y., Chen, X., Wang, Z., Meek, C. J., McLean, J. L., Yang, Y., Yuan, C., Rochet, J., Liu, F., & Xu, R. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03041-w · Cited by 81
“Overall, our proteomics data indicate that the AD neuroimmune organoids successfully replicate the major disrupted pathways and molecular signatures of AD observed in patients, corroborating our fi ndings on cellular dysfunction in these organoids.”
Hensman Moss, D. J., Flower, M. D., Lo, K. K., Miller, J. R. C., van Ommen, G.-J. B., ’t Hoen, P. A. C., Stone, T. C., Guinee, A., Langbehn, D. R., Jones, L., et al. (2017) · Scientific Reports · doi:10.1038/srep44849 · Cited by 55
“Recently Hong, et al. 38 showed that early in the disease process, before plaque formation, microglia and complement activation drive synaptic loss, a process that may reflect reactivation of developmental synaptic pruning 59 .”
BackgroundThe Astrocytic cAMP Pathway in Health and Disease
Zhou, Z., Ikegaya, Y., & Koyama, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030779 · Cited by 67
“C3 then compromises neuronal morphology and induces microglia-dependent synapse loss [130,131].”
BackgroundCarrillo, G. L., Ballard, V. A., Glausen, T. G., Boone, Z., Teamer, J., Hinkson, C. L., Wohlfert, E. A., Blader, I. J., & Fox, M. A. (2020) · Glia · doi:10.1002/glia.23816 · Cited by 58
“In cases where microglia have been implicated in the pathological loss of synapses, it appears to be mediated through the complement pathway (Hong et al. 2016; Sekar et al. 2016; Vasek et al. 2016; Hammond et al. BioRxiv), a similar pathway used to prune the excess of excitatory synapses during…”
BackgroundMethodInfluentialVan den Broek, B., Pintelon, I., Hamad, I., Kessels, S., Haidar, M., Hellings, N., Hendriks, J. J. A., Kleinewietfeld, M., Brône, B., Timmerman, V., et al. (2020) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12022 · Cited by 55
“EVs from diverse origins are described to target microglia (Bahrini, Song, Diez, & Hanayama, 2015; Bialas et al., 2017; Fauré et al., 2006; Hong et al., 2016; Lui et al., 2016, Paolicelli et al., 2017).”
Vandendriessche, C., Balusu, S., Van Cauwenberghe, C., Brkic, M., Pauwels, M., Plehiers, N., Bruggeman, A., Dujardin, P., Van Imschoot, G., Van Wonterghem, E., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01245-z · Cited by 56
Bourel, J., Planche, V., Dubourdieu, N., Oliveira, A., Séré, A., Ducourneau, E.-G., Tible, M., Maitre, M., Lesté-Lasserre, T., Nadjar, A., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105533 · Cited by 58
Lee, S., Salazar, S. V., Cox, T. O., & Strittmatter, S. M. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.2983-18.2018 · Cited by 55
“L; Jankowsky et al., 2004; Janus et al., 2015; Hong et al., 2016).”
BackgroundLiu, X.-G., Zhang, L., Lu, S., Liu, D.-Q., Zhang, L.-X., Yu, X.-L., & Liu, R.-T. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s240953 · Cited by 55
Maurya, S. K., Bhattacharya, N., Mishra, S., Bhattacharya, A., Banerjee, P., Senapati, S., & Mishra, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.654489 · Cited by 64
“Microglia and the innate immune system are essential for synaptic pruning to impart changes to the neural world around them and suggested their contribution to both neurological and psychiatric illnesses (Stevens et al., 2007; Hong et al., 2016; Sekar et al., 2016; Vainchtein et al., 2018).”
BackgroundAberrant Complement System Activation in Neurological Disorders
Ziąbska, K., Ziemka‐Nałęcz, M., Pawelec, P., Sypecka, J., & Zalewska, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094675 · Cited by 56
Zhang, M., & Bian, Z. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.687973 · Cited by 55
“It has been reported that, in mouse models of AD, C1q levels were increased and associated with synaptic loss before apparent plaque deposition (Hong et al., 2016), and inhibition of C1q expression reduced the number of phagocytic microglia, and may be involved in early synaptic loss (Stevens et al.”
BackgroundCirculating C1q levels in health and disease, more than just a biomarker
van de Bovenkamp, F. S., Dijkstra, D. J., van Kooten, C., Gelderman, K. A., & Trouw, L. A. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.10.010 · Cited by 68
“In line with these human data, C1q levels in the brain are increased in mouse models of Alz-heimer ’ s disease (Hong et al., 2016).”
ResultGómez-Arboledas, Á., Carvalho, K., Balderrama-Gutierrez, G., Chu, S., Liang, H. Y., Schartz, N. D., Selvan, P., Petrisko, T. J., Pan, M. A., Mortazavi, A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01416-6 · Cited by 61
“Among all the advances in the knowledge of the mechanism driving complement mediated synaptic pruning, we should highlight recent work showing that inhibition of C1q or C3 can successfully reduce the excessive synaptic loss that occurs with AD progression(14, 33).”
BackgroundGomes, P., Tzouanou, F., Skolariki, K., Vamvaka-Iakovou, A., Noguera-Ortiz, C., Tsirtsaki, K., Waites, C. L., Vlamos, P., Sousa, N., Costa-Silva, B., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114183 · Cited by 55
“Glial cells have been shown to play an important role in this process (Eroglu and Barres, 2010) in a complement-dependent manner and are triggered by neuronal activity (Hong et al., 2016; Schafer et al., 2012).”
Astrocyte-dependent circuit remodeling by synapse phagocytosis
Park, J., & Chung, W. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102732 · Cited by 62
Redefining our vision: an updated guide to the ocular immune system
Wu, M., Fletcher, E. L., Chinnery, H. R., Downie, L. E., & Mueller, S. N. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01064-y · Cited by 63
“synapses and circuits, with dysregulated phagocytosis implicated in many neurodegenerative disorders 133–135 .”
Peineau, S., Rabiant, K., Pierrefiche, O., & Potier, B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.018 · Cited by 60
18F-FDG-PET in Mouse Models of Alzheimer's Disease
Bouter, C., & Bouter, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00071 · Cited by 59
Liu, D., Zhao, Y., Qi, Y., Gao, Y., Tu, D., Wang, Y., Gao, H., & Zhou, H. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01925-y · Cited by 57
“Synapse loss in the hippocampus in the APP/PS1 mice occurs by 4 months of age [44].”
BackgroundMaes, M. H. J., Vojdani, A., Sirivichayakul, S., Barbosa, D. S., & Kanchanatawan, B. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02343-8 · Cited by 57
Complement cascade functions during brain development and neurodegeneration
Fatoba, O., Itokazu, T., & Yamashita, T. (2021) · FEBS Journal · doi:10.1111/febs.15772 · Cited by 60
Mohammadi, N., Asle‐Rousta, M., Rahnema, M., & Amini, R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174506 · Cited by 59
Islam, F., Islam, M. R., Meem, A. F. K., Nafady, M. H., Islam, M. R., Akter, A., Mitra, S., Alhumaydhi, F. A., Emran, T. B., Khusro, A., et al. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.136020 · Cited by 56
RetractedLi, C., Liu, B., Xu, J., Jing, B., Guo, L., Wang, L., Wang, M., Zhang, H., He, Q., Yu, X., et al. (2023) · Theranostics · doi:10.7150/thno.76553 · Cited by 59
“Here, we showed that C3 also localized to synapses in the mPFC after CMS exposure like C1q localizing to synapses in Alzheimer’s disease (AD) mouse model [28].”
BackgroundSu, Y., Huang, Y., Kou, Q., Lu, L., Jiang, H., Li, X., Gui, R., Huang, R., Huang, X., Ma, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202301361 · Cited by 57
Profaci, C. P., Harvey, S. S., Bajc, K., Zhang, T. Z., Jeffrey, D. A., Zhang, A. Z., Nemec, K. M., Davtyan, H., O’Brien, C. A., McKinsey, G. L., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.07.015 · Cited by 64
Glial Na+‐dependent ion transporters in pathophysiological conditions
Boscia, F., Begum, G., Pignataro, G., Sirabella, R., Cuomo, O., Casamassa, A., Sun, D., & Annunziato, L. (2016) · Glia · doi:10.1002/glia.23030 · Cited by 59
Microglial dysfunction as a key pathological change in adrenomyeloneuropathy
Gong, Y., Sasidharan, N., Laheji, F., Frosch, M., Musolino, P., Tanzi, R., Kim, D. Y., Biffi, A., El Khoury, J., & Eichler, F. (2017) · Annals of Neurology · doi:10.1002/ana.25085 · Cited by 54
“synaptic pruning attributed to excessive microglial activation may instead promote neurodegeneration, as also observed in many neurodegenerative disease models.(10,36) By what mechanism are MFGE8 and C1q upregulated in Abcd1 mouse spinal cord? In vitro CRISPR knockout of ABCD1 gene in N9 microglia did not show upregul…”
Kalinin, S., González‐Prieto, M., Scheiblich, H., Lisi, L., Kusumo, H., Heneka, M. T., Madrigal, J. L. M., Pandey, S. C., & Feinstein, D. L. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1184-7 · Cited by 56
Nanoparticulate matter exposure results in neuroinflammatory changes in the corpus callosum
Babadjouni, R., Patel, A. B., Liu, Q., Shkirkova, K., Lamorie‐Foote, K., Connor, M., Hodis, D. M., Cheng, H., Sioutas, C., Morgan, T. E., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206934 · Cited by 58
Föcking, M., Sabherwal, S., Cates, H. M., Scaife, C., Dicker, P., Hryniewiecka, M., Wynne, K. J., Rutten, B. P. F., Lewis, G., Cannon, M. D., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0306-z · Cited by 58
Extracellular microvesicles promote microglia‐mediated pro‐inflammatory responses to ethanol
Crews, F. T., Zou, J., & Coleman, L. G. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24813 · Cited by 58
“…of Alzheimer's disease (Keren- Shaul et al., 2017), C1q is involved in microglial pruning of synapses and microglial activation of astrocytes (Hong et al., 2016; Stephan et al., 2013), CX3CR1 regulates microglia activation state via interaction with neuron- derived fractalkine (CX3CL1)…”
BackgroundRegulation of microglia population dynamics throughout development, health, and disease
Hammond, B. P., Manek, R., Kerr, B. J., Macauley, M. S., & Plemel, J. R. (2021) · Glia · doi:10.1002/glia.24047 · Cited by 65
Wu, C., Zhang, S., Sun, H., Li, A., Hou, F., Qi, L., & Liao, H. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03086-8 · Cited by 54
“The increased synapse elimination by microglia has also been reported in various brain diseases, such as Alzheimer’s disease [7–9], schizophrenia [10], neuropsychiatric lupus [11], depression [12], and sepsis-associated encephalopathy [13], and is intimately involved in disease progression.”
BackgroundMicroglial innate memory and epigenetic reprogramming in neurological disorders
Martins-Ferreira, R., Leal, B., Costa, P. P., & Ballestar, E. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101971 · Cited by 54
Neuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimer’s Disease
Eren, E., Leoutsakos, J.-M., Troncoso, J., Lyketsos, C. G., Oh, E. S., & Kapogiannis, D. (2022) · Cells · doi:10.3390/cells11030436 · Cited by 53
Seicol, B. J., Lin, S., & Xie, R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.846804 · Cited by 64
“However, C1q and the complement cascade also sculpt neural circuitry through synapse elimination during development and disease (Schafer et al., 2012; Hong et al., 2016a,b).”
BackgroundPeripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms
Brubaker, W. D., Crane, A., Johansson, J. U., Yen, K., Garfinkel, K., Mastroeni, D., Asok, P., Bradt, B., Sabbagh, M., Wallace, T. L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.03.010 · Cited by 53
Synapse Pruning: Mitochondrial ROS with Their Hands on the Shears
Cobley, J. N. (2018) · BioEssays · doi:10.1002/bies.201800031 · Cited by 53
Rasmussen, K. L., Nordestgaard, B. G., Frikke‐Schmidt, R., & Nielsen, S. F. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.223 · Cited by 53
“As synaptic loss is a pathological correlate of cognitive decline and occurs in mild cognitive impairment and AD before onset of plaques [10,36], this may either drive or contribute to the early preclinical pathogenesis of AD.”
BackgroundThe Promises and Challenges of Erythropoietin for Treatment of Alzheimer’s Disease
Sun, J., Martin, J. M., Vanderpoel, V., & Sumbria, R. K. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08524-y · Cited by 57
Ma, X., Chen, K., Cui, Y., Huang, G., Nehme, A., Zhang, L., Li, H., Wei, J., Liong, K., Liu, Q., et al. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24641 · Cited by 58
“…in brain pathologies, microglia are increasingly known to play a role in normal brain development (Colonna & Butovsky, 2017; Dagher et al., 2015; Hong et al., 2016; Parkhurst et al., 2013; Salter & Stevens, 2017; Sarlus & Heneka, 2017; Spangenberg et al., 2019; Szalay et al., 2016; Tremblay,…”
BackgroundPICALM Alzheimer’s risk allele causes aberrant lipid droplets in microglia
Kozlova, A., Zhang, S., Sudwarts, A., Zhang, H., Smirnou, S., Byeon, S. K., Thapa, C., Sun, X., Stephenson, K., Zhao, X., et al. (2025) · Nature · doi:10.1038/s41586-025-09486-x · Cited by 69
Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
Spotorno, N., Strandberg, O. T., Vis, G., Stomrud, E., Nilsson, M., & Hansson, O. (2022) · Brain · doi:10.1093/brain/awac343 · Cited by 56
“Considering that glial activation appears to have a significant role in the pathophysiology of Alzheimer’s disease 21–23 and, possibly, in the response to anti-A β disease-modifying therapies, 8 we further investigated the association between cortical diffusion and plasma levels of glial fibrillary…”
Necroptosis and Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Opportunities
Zhang, R., Song, Y., & Su, X. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220809 · Cited by 56
Tipping points in neurodegeneration
Simons, M., Levin, J., & Dichgans, M. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.031 · Cited by 50
Synaptoimmunology - roles in health and disease
Nisticò, R., Salter, E., Nicolas, C., Feligioni, M., Mango, D., Bortolotto, Z. A., Gressens, P., Collingridge, G. L., & Peineau, S. (2017) · Molecular Brain · doi:10.1186/s13041-017-0308-9 · Cited by 52
“Thus the authors suggest that microgliamediated synapse loss early in AD may be due to a pathological reactivation of a developmental program of synaptic pruning [139].”
BackgroundRotterman, T. M., Akhter, E. T., Lane, A. R., MacPherson, K. P., García, V. V., Tansey, M. G., & Álvarez, F. J. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.2945-17.2019 · Cited by 61
“Neuroinflammation influences synapse stability and loss (Hong et al., 2016; Nisticò et al., 2017) and after PNI, there is intense microgliosis in the spinal cord side ipsilateral to the injury and sometimes infiltration of myeloid cells, including chemokine receptor 2 (CCR2)-expressing macrophages.”
BackgroundThe Neuroprotective Role of Reactive Astrocytes after Central Nervous System Injury
Boghdadi, A. G., Teo, L., & Bourne, J. A. (2020) · Journal of Neurotrauma · doi:10.1089/neu.2019.6938 · Cited by 57
“24 37–39 Although capable of inducing the formation of new functional synapses in vitro through glypican, hevin, and thrombospondin (Thbs) secretion, A1 astrocytes induced the formation of fewer, functionally weaker synapses, compared to resting astrocytes.”
The role of glia in protein aggregation
Li, Q., & Haney, M. S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105015 · Cited by 52
Cytokine signaling convergence regulates the microglial state transition in Alzheimer’s disease
Lau, S.-F., Fu, A. K. Y., & Ip, N. Y. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03810-0 · Cited by 52
Comparative Review of Microglia and Monocytes in CNS Phagocytosis
Andoh, M., & Koyama, R. (2021) · Cells · doi:10.3390/cells10102555 · Cited by 62
McAlpin, B. R., Mahalingam, R., Singh, A. K., Dharmaraj, S., Chrisikos, T. T., Boukelmoune, N., Kavelaars, A., & Heijnen, C. J. (2021) · Theranostics · doi:10.7150/thno.67410 · Cited by 53
“Interestingly, a mouse model of Alzheimer’s revealed that early synapse loss in the hippocampus is specific to PSD95+ puncta, but not synaptophysin+ puncta, and mediated by aberrant synaptic pruning by microglia [57].”
BackgroundExploring the dual character of metformin in Alzheimer's disease
Ning, P., Luo, A., Mu, X. L., Xu, Y., & Li, T. X. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108966 · Cited by 53
Tran, K. M., Kawauchi, S., Kramár, E. A., Rezaie, N., Liang, H. Y., Sakr, J. S., Gomez-Arboledas, A., Arreola, M. A., Cunha, C. D., Phan, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00598-4 · Cited by 50
Microglia directly associate with pericytes in the central nervous system
Morris, G. P., Foster, C. G., Courtney, J., Collins, J. M., Cashion, J. M., Brown, L. S., Howells, D. W., DeLuca, G. C., Canty, A. J., King, A. E., et al. (2023) · Glia · doi:10.1002/glia.24371 · Cited by 54
“Cases were considered to have AD if, at a minimum, they were defined as intermediate or high on the NIA-Reagan criteria (Hyman et al., 2012).”
BackgroundNovel Evasion Mechanisms of the Classical Complement Pathway
Garcia, B. L., Zwarthoff, S. A., Rooijakkers, S. H. M., & Geisbrecht, B. V. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600863 · Cited by 50
“The involvement of excessive CP activation in human disease was recently cast into the spotlight because of its causal link to schizophrenia (109) and Alzheimer’s disease (110), not to mention other devastating diseases in which the contribution of the CP to pathology has been longer appreciated (111, 112).”
BackgroundComplement in the fundamental processes of the cell
Hawksworth, O. A., Coulthard, L. G., & Woodruff, T. M. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.11.010 · Cited by 51
Wang, E., Zhu, H., Wang, X., Gower, A. C., Wallack, M., Blusztajn, J. K., Kowall, N. W., & Qiu, W. Q. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160677 · Cited by 54
Neural synchronization in Alzheimer's disease
Aron, L., & Yankner, B. A. (2016) · Nature · doi:10.1038/540207a · Cited by 55
C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus
van Schaarenburg, R. A., Magro‐Checa, C., Bakker, J. A., Teng, Y. K. O., Bajema, I. M., Huizinga, T. W. J., Steup‐Beekman, G. M., & Trouw, L. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00647 · Cited by 53
“A neuroprotective role for C1q was reported in the context of beta-amyloid-induced neurotoxicity (10, 11), while on the other hand, C1q is reported to be involved in damage in the context of Alzheimer’s disease (12).”
BackgroundIn Vivo Imaging of Microglial Calcium Signaling in Brain Inflammation and Injury
Tvrdík, P., & Kalani, M. Y. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112366 · Cited by 56
“In an independent aggravating mechanism, microglia exposed to Aβ engage in excessive synapse pruning in a complement- and CR3 (CD11b/CD18)-dependent fashion, leading, at least in the mouse model, to synapse loss before plaque formation [94].”
BackgroundBuechler, J., & Salinas, P. C. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00038 · Cited by 51
Ocular Dominance Plasticity in Binocular Primary Visual Cortex Does Not Require C1q
Welsh, C. A., Stephany, C.-É., Sapp, R. W., & Stevens, B. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1011-19.2019 · Cited by 55
“C1q is significantly upregulated and mediates pathological synapse loss in models of Alzheimer’s and neurodegenerative disease (Hong et al., 2016; Lui et al., 2016; Vasek et al., 2016; Dejanovic et al., 2018).”
BackgroundSelf-citationLi, S., Hayden, E. Y., Garcia, V. J., Fuchs, D.-T., Sheyn, J., Daley, D. A., Rentsendorj, A., Torbati, T., Black, K. L., Rutishauser, U., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00049 · Cited by 51
Self-citationMoreno-Rodriguez, M., Perez, S. E., Nadeem, M., Malek-Ahmadi, M., & Mufson, E. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1723-x · Cited by 51
“Microglia activation, associated with high Iba1 levels that modulate synapse loss [94] and microglia reactivity, maybe related to the induction of pro-inflammatory genes and the expression of complement-associated factors following neuronal death [95].”
Contributions of monocytes to nervous system disorders
Garré, J. M., & Yang, G. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1672-3 · Cited by 57
“RTT, microglial cells have been shown to contribute to neuronal circuit deficits in Mecp2 mice [76] as well as in Tg-AD mice [77].”
Microglia: Lifelong modulator of neural circuits
Ikegami, A., Haruwaka, K., & Wake, H. (2019) · Neuropathology · doi:10.1111/neup.12560 · Cited by 52
“been published on disturbed synaptic modification due to excess synapse pruning by activated microglia in AD or schizophrenia.(23,50,51) To enable suitable, balanced maintenance of brain homeostasis, microglia need to remain in the physiological and ramified state in healthy brains.”
BackgroundRegulation of microglia by glutamate and its signal pathway in neurodegenerative diseases
Zhang, X., Wang, D., Zhang, B., Zhu, J., Zhou, Z., & Cui, L. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.001 · Cited by 56
Potential neurobiological links between social isolation and Alzheimer's disease risk
Drinkwater, E., Davies, C., & Spires‐Jones, T. L. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15373 · Cited by 58
Gregersen, E., Betzer, C., Kim, W. S., Kovács, G. E., Reimer, L., Halliday, G. M., Thiel, S., & Jensen, P. H. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02225-9 · Cited by 52
Role of Molecular Hydrogen in Ageing and Ageing‐Related Diseases
Fu, Z., Zhang, J., & Zhang, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2249749 · Cited by 57
“This results in them becoming overactive in neurodegeneration, eventually leading to more microglia becoming senescent [131].”
Suspected non-Alzheimer's pathology – Is it non-Alzheimer's or non-amyloid?
Dani, M., Brooks, D. J., & Edison, P. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.02.003 · Cited by 54
Autoimmune phenotypes in schizophrenia reveal novel treatment targets
Severance, E. G., Dickerson, F., & Yolken, R. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.005 · Cited by 58
“As described in rodent models, complement proteins functioned in synapse formation and elimination during neuronal development as well as in response to the presence of brain pathogens in adults (Bialas & Stevens, 2013; Boulanger, 2009; Fourgeaud & Boulanger, 2007; Hong et al., 2016; Lui et al., 2016; Presumey, Bialas…”
Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease
Selles, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179925 · Cited by 50
“In AD models, A (cid:2) Os greatly increase brain levels of C3, one of the proteins in the complement cascade, which is tightly correlated to synapse loss [191].”
Developmental roles of microglia: A window into mechanisms of disease
Anderson, S., & Vetter, M. L. (2018) · Developmental Dynamics · doi:10.1002/dvdy.1 · Cited by 54
“C1q deposits on synapses before Aβ deposition, and inhibition of C1q, C3, or receptor CR3 attenuates early synaptic loss.”
BackgroundResultInfluentialEarly complement genes are associated with visual system degeneration in multiple sclerosis
Fitzgerald, K. C., Kim, K., Smith, M. D., Aston, S. A., Fioravante, N., Rothman, A. M., Krieger, S., Cofield, S. S., Kimbrough, D. J., Bhargava, P., et al. (2019) · Brain · doi:10.1093/brain/awz188 · Cited by 49
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
Konijnenberg, E., Tijms, B. M., Gobom, J., Dobricic, V., Bos, I., Vos, S., Tsolaki, M., Verhey, F., Popp, J., Martinez-Lage, P., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00628-z · Cited by 50
Therapeutic potential of a TrkB agonistic antibody for Alzheimer's disease
Wang, S., Yao, H., Xu, Y., Hao, R., Zhang, W., Liu, H., Huang, Y., Guo, W., & Lu, B. (2020) · Theranostics · doi:10.7150/thno.44165 · Cited by 53
“Many previous studies using APP/PS1 mice have also used hippocampus to examine synaptic changes [83].”
MethodModeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors
Pasqualini, C., Kozaki, T., Bruschi, M., Nguyen, T. H. H., Minard‐Colin, V., Castel, D., Grill, J., & Ginhoux, F. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.018 · Cited by 59
Peterson, S. L., Li, Y., Sun, C., Wong, K. A., Leung, K. S., de Lima, S., Hanovice, N. J., Yuki, K., Stevens, B., & Benowitz, L. I. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0555-21.2021 · Cited by 53
“…Anderson, 2014), including clearance of myelin (Kopper and Gensel, 2018), dead cells (Silverman et al., 2019), and synapses (Schafer et al., 2012; Hong et al., 2016; Alawieh et al., 2020); neuroprotection (van Beek et al., 2001; Yu et al., 2012; Benoit et al., 2013); and lesion modification…”
BackgroundInfluentialSelf-citationChatterjee, M., Özdemir, S., Kunadt, M., Koel‐Simmelink, M., Boiten, W., Piepkorn, L., Pham, T. V., Chiasserini, D., Piersma, S. R., Knol, J. C., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13066 · Cited by 47
Regulation of microglial physiology by the microbiota
Cook, J., & Prinz, M. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2125739 · Cited by 49
“Moreover, various neurodegenerative pathologies including Alzheimer’s disease have been suggested to encompass some degree of aberrant synaptic elimination by microglia.(28) Thus, microglia are capable of directly shaping CNS architecture through a variety of mechanisms.”
BackgroundEffect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease
Serrano-Pozo, A., Li, Z., Noori, A., Nguyen, H. N., Mezlini, A., Li, L., Hudry, E., Jackson, R. J., Hyman, B. T., & Das, S. (2021) · Nature Aging · doi:10.1038/s43587-021-00123-6 · Cited by 49
Abey, A. S., Davies, D., Goldsbury, C. S., Buckland, M. E., Valenzuela, M., & Duncan, T. (2020) · Brain Pathology · doi:10.1111/bpa.12893 · Cited by 54
“An increasing number of recent studies posit that oligomeric Aβ or p-tau represent pathological species that may drive cognitive decline through synaptic dysfunction (21,22).”
BackgroundCong, Q., Soteros, B. M., Huo, A., Li, Y., Tenner, A. J., & Sia, G. M. (2022) · Glia · doi:10.1002/glia.24114 · Cited by 49
“, 2016) and Alzheimer's disease associated memory loss (Hong et al., 2016; Shi et al., 2017).”
BackgroundHao, X., Li, Z., Li, W., Katz, J., Michalek, S. M., Barnum, S. R., Pozzo‐Miller, L. D., Saito, T., Saido, T. C., Wang, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816640 · Cited by 62
“Previous studies have reported that the complement system is hyper-activated in the brain tissues from AD patients and mouse models (18, 19), inhibition or lack of complement components could ameliorate AD-relevant characters in multiple mouse models of AD (18, 50, 51).”
BackgroundBrain–immune interaction mechanisms: Implications for cognitive dysfunction in psychiatric disorders
Zhao, F., Li, B., Yang, W., Ge, T., & Cui, R. (2022) · Cell Proliferation · doi:10.1111/cpr.13295 · Cited by 55
“and may contribute to the clearance of Aβ by microglia in the brain.(128,129)”
BackgroundA lysosomal regulatory circuit essential for the development and function of microglia
Iyer, H., Shen, K., Meireles, A. M., & Talbot, W. S. (2022) · Science Advances · doi:10.1126/sciadv.abp8321 · Cited by 49
“…prolonged activation of inflammatory pathways in AD results in neurotoxicity and indiscriminate loss of viable cells leading to cognitive defects ( 74 – 78 ), our observation that hyper-activation of Tfeb and Tfe3 may down-regulate immune pathways in the macrophage lineage may offer a key insight…”
The multiple faces of extracellular vesicles released by microglia: Where are we 10 years after?
Gabrielli, M., Raffaele, S., Fumagalli, M., & Verderio, C. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.984690 · Cited by 59
Metadata
- Authors
- Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., Lemere, C. A., Selkoe, D. J., & Stevens, B.
- Affiliations
- Boston Children's Hospital (US)
- Brigham and Women's Hospital (US)
- University of California, San Francisco (US)
- Stanford Medicine (US)
- Broad Institute (US)
- Corresponding author
- Beja-Glasser, Victoria F.
- Nfonoyim, Bianca M.
- Stevens, Beth
- ORCID
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 712-716
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5094372
- OpenAlex
- W2314634699
- Cited by
- 3,343
- References
- 33
- Citations by year
- 2026: 415 · 2025: 391 · 2024: 384 · 2023: 388 · 2022: 324 · 2021: 363 · 2020: 306 · 2019: 260 · 2018: 240 · 2017: 198 · 2016: 69
- FWCI
- 140.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Edward R. and Anne G. Lefler Fellowship
- Coins for Alzheimer's Research Trust
- Fidelity Biosciences Research Initiative
- JPB Foundation
- National Institutes of Health (AG000222)
- National Institute of Neurological Disorders and Stroke-NIH (R01NS083845)
- National Institute on Aging-NIH (1RF1AG051496A)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- Alzheimer's disease, synaptic loss, complement system, microglia, C1q, CR3, complement C3, soluble amyloid-beta oligomers, neuroinflammation, synaptic pruning, hippocampal long-term potentiation, phagocytosis, mouse model
- MeSH terms
- Disks Large Homolog 4 Protein, Alzheimer Disease, Animals, Cognition Disorders, Complement Pathway, Classical, Disease Models, Animal, Membrane Proteins, Phagocytosis, Synapses, Up-Regulation, Complement C1q, Macrophage-1 Antigen, Amyloid beta-Peptides, Synaptophysin, Microglia, Long-Term Potentiation, Mice, Knockout, Mice, Guanylate Kinases, CA1 Region, Hippocampal, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.